Cytarabine plus G-CSF is more effective than cyclophosphamide plus G-CSF as a stem cell mobilization regimen in multiple myeloma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F19%3AA20021XJ" target="_blank" >RIV/61988987:17110/19:A20021XJ - isvavai.cz</a>

Výsledek na webu

<a href="https://www.nature.com/articles/s41409-018-0396-x" target="_blank" >https://www.nature.com/articles/s41409-018-0396-x</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41409-018-0396-x" target="_blank" >10.1038/s41409-018-0396-x</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Cytarabine plus G-CSF is more effective than cyclophosphamide plus G-CSF as a stem cell mobilization regimen in multiple myeloma

Popis výsledku v původním jazyce

Cyclophosphamide (Cy) plus granulocyte-colony stimulating factor (G-CSF) is currently a standard regimen for hematopoietic stem cell (HSC) mobilization in patients with multiple myeloma (MM). However, cytarabine (AraC) in intermediate doses plus G-CSF seems to have a higher mobilization efficacy. The aim of this study was to retrospectively compare mobilization using AraC and Cy. Thirty consecutive MM patients were mobilized by Cy + G-CSF, and the subsequent 40 patients by AraC + G-CSF. Both groups were comparable. The target yield of 10 x 10(6) CD34+ cells/kg (for tandem and 2 additional transplantations) was achieved in 98% (AraC) and 57% (Cy) of patients (p &lt; 0.0001) by 1.2 and 2.1 apheresis (means), and by single apheresis in 83 and 17% of patients, respectively. AraC mobilization resulted in higher peak concentration of CD34+ cells in blood (median 238.0 vs. 87.9/mu L, p &lt; 0.0001) and higher CD34+ yield (median 28.6 x 10(6) vs. 10.4 x 10(6)/kg, p &lt; 0.0001) compared to Cy mobilization. Toxicities were comparable except for thrombocytopenia gr. 4, observed in 50% of patients after AraC (Cy 7%). In view of these results, we conclude that mobilization with AraC plus G-CSF is very effective with acceptable toxicity and could be considered in MM patients with planned or expected higher numbers of transplantations.

Název v anglickém jazyce

Cytarabine plus G-CSF is more effective than cyclophosphamide plus G-CSF as a stem cell mobilization regimen in multiple myeloma

Popis výsledku anglicky

Cyclophosphamide (Cy) plus granulocyte-colony stimulating factor (G-CSF) is currently a standard regimen for hematopoietic stem cell (HSC) mobilization in patients with multiple myeloma (MM). However, cytarabine (AraC) in intermediate doses plus G-CSF seems to have a higher mobilization efficacy. The aim of this study was to retrospectively compare mobilization using AraC and Cy. Thirty consecutive MM patients were mobilized by Cy + G-CSF, and the subsequent 40 patients by AraC + G-CSF. Both groups were comparable. The target yield of 10 x 10(6) CD34+ cells/kg (for tandem and 2 additional transplantations) was achieved in 98% (AraC) and 57% (Cy) of patients (p &lt; 0.0001) by 1.2 and 2.1 apheresis (means), and by single apheresis in 83 and 17% of patients, respectively. AraC mobilization resulted in higher peak concentration of CD34+ cells in blood (median 238.0 vs. 87.9/mu L, p &lt; 0.0001) and higher CD34+ yield (median 28.6 x 10(6) vs. 10.4 x 10(6)/kg, p &lt; 0.0001) compared to Cy mobilization. Toxicities were comparable except for thrombocytopenia gr. 4, observed in 50% of patients after AraC (Cy 7%). In view of these results, we conclude that mobilization with AraC plus G-CSF is very effective with acceptable toxicity and could be considered in MM patients with planned or expected higher numbers of transplantations.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

BONE MARROW TRANSPL

ISSN

0268-3369

e-ISSN

1476-5365

Svazek periodika

54

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

1107

Strana od-do

1114-7

Kód UT WoS článku

000473724200021

EID výsledku v databázi Scopus

2-s2.0-85056829713